Journal of
Clinical Medicine
Article
Efficacy of a Smartphone-Based Virtual Companion to Treat
Insomniac Complaints in the General Population: Sleep Diary
Monitoring Versus an Internet Autonomous Intervention
PierrePhilip1,2,3,*,LucileDupuy4 ,PatriciaSagaspe1,2,3 ,EtiennedeSevin1,2,MarcAuriacombe1,2 ,
JacquesTaillard1,2 ,Jean-ArthurMicoulaud-Franchi1,2,3andCharlesM.Morin5,6
1 SANPSY,UMR6033,UniversityofBordeaux,F-33000Bordeaux,France;
patricia.sagaspe@chu-bordeaux.fr(P.S.);etienne.de-sevin@u-bordeaux.fr(E.d.S.);
marc.auriacombe@u-bordeaux.fr(M.A.);jack.taillard@gmail.com(J.T.);
jean-arthur.micoulaud-franchi@chu-bordeaux.fr(J.-A.M.-F.)
2 CNRS,SANPSY,UMR6033,F-33000Bordeaux,France
3 ServicedeMédecineUniversitaireduSommeil,CHUdeBordeaux,PlaceAmélieRaba-Léon,
F-33076Bordeaux,France
4 BordeauxPopulationHealthResearchCentre,UniversityofBordeaux,Inserm,UMRU1219,
F-33000Bordeaux,France;lucile.dupuy@u-bordeaux.fr
5 ÉcoledePsychologie,UniversitéLaval,Québec,QCG1V0A6,Canada;cmorin@psy.ulaval.ca
6 CentreD’étudedesTroublesduSommeil,CentredeRechercheCERVO,InstitutUniversitaireenSanté
MentaledeQuébec,Québec,QCG1A0A6,Canada
* Correspondence:pr.philip@free.fr;Tel.:+33-557-820-172
Citation:Philip,P.;Dupuy,L.; Abstract:(1)Background:Insomniaisthemostprevalentsleepdisorderworldwideandcognitive
Sagaspe,P.;deSevin,E.;Auriacombe, behavioraltherapyisthefront-linetreatment. Digitalhealthtechnologieshavearoletoplayin
M.;Taillard,J.;Micoulaud-Franchi, screeninganddeliveringinterventionsremotelyandwithouttheneedforhumanintervention.The
J.-A.;Morin,C.M.Efficacyofa KANOPEEapp,whichprovidesascreeningandbehavioralinterventionforinsomniasymptoms
Smartphone-BasedVirtual throughaninteractionwithavirtualagent,showedencouragingresultsinpreviousstudiesduring
CompaniontoTreatInsomniac
andaftertheCOVID-19lockdown,buthasnotyetbeenevaluatedinacontrolledstudy.Thisstudy
ComplaintsintheGeneral
aims at comparing the benefits of KANOPEE, a smartphone application dealing with insomnia
Population:SleepDiaryMonitoring
complaints,withanotherapplicationproposinganelectronicsleepdiarynamed“MySleepDiary”.
VersusanInternetAutonomous
Theacceptanceandpotentialbenefitsofthesedigitalsolutionsaretestedinreal-lifesettings(i.e.,
Intervention.J.Clin.Med.2022,11,
withoutsolicitinghumanmedicalresources)andinthegeneralpopulation.(2)Methods:Subjects
4387. https://doi.org/10.3390/
jcm11154387 were included if they downloaded one of the apps between December 2020 and October 2021,
andwereoflegalage. BothappswereavailableondownloadingplatformsinFrance. Primary
AcademicEditor:RoyP.C.Kessels
outcomewasInsomniaSeverityIndex(ISI),andsecondaryoutcomesweretotalsleeptime(TST),
Received:4July2022 sleep efficiency (SE) and wake time after sleep onset (WASO). (3) Results: A total of 535 users
Accepted:26July2022 completedtheinterventionwithKANOPEEand489userscompletedMySleepDiary,bothfor17days.
Published:28July2022 KANOPEE users improved their ISI score significantly more than sleep diary users (interaction
Time*Group:F(2,2002)=17.3,p<0.001).Similarresultswerefoundfornocturnalsleepparameters
Publisher’sNote:MDPIstaysneutral
withregardtojurisdictionalclaimsin (TST) (KANOPEE users gained 48 min of sleep after intervention, while My Sleep Diary users
publishedmapsandinstitutionalaffil- gainedonly16minofsleep), andparticularlyinthepopulationwithmoderatetosevereinitial
iations. sleepcomplaints(F(4,1980)=8.9,p<0.001).Othersleepmarkers(SEandWASO)weresignificantly
improvedintheKANOPEEuserscomparedtothesleepdiaryones(p<0.001). (4)Conclusions:
KANOPEEprovidessignificantlygreaterbenefitsthananelectronicsleepdiaryregardingreduction
ofinsomniacomplaintsandestimatednocturnalsleepcharacteristicsinaself-selectedsampleofthe
Copyright: © 2022 by the authors.
generalpopulation.PopulationwiththemostsevereinitialISIscore(≥15)benefitedthemostfrom
Licensee MDPI, Basel, Switzerland.
theKANOPEEAppcomparedtofillingupasimplesleepdiary.
This article is an open access article
distributed under the terms and
Keywords:insomnia;behavioralintervention;virtualagents;generalpopulation
conditionsoftheCreativeCommons
Attribution(CCBY)license(https://
creativecommons.org/licenses/by/
4.0/).
J.Clin.Med.2022,11,4387.https://doi.org/10.3390/jcm11154387 https://www.mdpi.com/journal/jcm
J.Clin.Med.2022,11,4387 2of11
1. Introduction
Insomniaisthemostprevalentsleepdisorder. Itispresentinabout10to20%ofthe
generalpopulation[1,2],andisfrequentlyassociatedwithmentalconditionssuchasmood
or anxiety disorders [3]. The ongoing COVID-19 crisis has increased the prevalence of
mentaldisorders[4,5]andinsomnia[6,7],confirminghowsleepandmentaldisordersare
closelyrelated.
Mostpatientssufferingfrominsomniaccomplaintsreceivehypnoticdrugs,butmedi-
cationsarenotrecommendedonalong-termbasisbecauseoftheirlackoflong-termefficacy
andpotentiallysevereside-effects. Therecommendedfirst-linetreatmentforinsomnia
disorder in adults is cognitive behavioral therapies (CBT-I) [1]. These usually rely on
multicomponentinterventionsincludingsleephygieneeducation(e.g.,avoidingcaffeine
andalcoholbeforebedtime),stimuluscontrolandtimeinbedreduction(i.e.,instructions
aimingatstrengtheningtheassociationbetweenbedandsleep).Inaddition,cognitiveinter-
ventionsaimedatcorrectingnegativethoughtsandbeliefsaboutsleepreinforceadherence
tobehavioralrecommendations[1,8].
Unfortunately,duetothediscrepancybetweenthehugenumberofpatientsneeding
treatment and the lack of trained healthcare practitioners, many patients do not have
accesstoCBT-I.Tocombatthisshortage,whichhasbeenaccentuatedbytheCOVID-19
crisis,autonomousdigitalsolutionsneedtobepromoted. Thesesolutions,calleddigital
CBT-I(d-CBT-I),haveshowntheirefficacyindeliveringCBT-I[9,10],reducinginsomnia
complaintsandimprovingsleepefficiency[11–15]. Morerecently,d-CBT-Ihavealsoshown
theirbenefitinreducinganxietysymptomsandimprovingpsychologicalwell-being[9,12].
Acceptanceofd-CBTbyusersisalsoakeyissueforpromotingdigitalhealthsolutions
in the general population. Interaction with digital solutions can be improved by using
embodiedconversationalagents,whichhavedemonstratedahighlevelofacceptancein
patientsreportingmentaldisorders[16]. In2020,ourteamlaunchedafreeapp(KANOPEE)
that is available on Google Play Store and Apple Store. Thanks to repeated interaction
withavirtualcompanion,theapphelpsscreeninsomniacomplaints,providesafollow-up
tool(sleepdiary)andgivesuserspersonalizedrecommendationsregardingsleephygiene,
stimuluscontrol,theoptimizationofsleepschedulesandphysicalactivity[17].
Todate,KANOPEEhasbeendownloadedmorethan23,000times,thuscreatingalarge
cohortfollowedbyourresearchteam.KANOPEEhasshownaverygoodlevelofacceptanceby
usersinthegeneralpopulationinareal-lifesetting[18].Arecentlypublishedopensingle-arm
studyof108KANOPEEusersshowedadecreaseininsomniacomplaintsandanimprovement
insleepdurationandsleepefficiency[19]. However,themainlimitationofthatstudywas
thelackofacontrolledcondition,precludinganydefinitiveconclusionsaboutwhethersleep
improvementisdirectlyattributabletousingKANOPEE.
Toovercomethislimitation,wedesignedaself-selected(non-randomized)controlled
studycomparingKANOPEEuserstousersofanon-interventionalapp,MySleepDiary,
an electronic sleep diary developed by our team and freely available on downloading
platformsinFrance.
Theobjectiveofthisstudy,conductedinareal-lifenaturalisticsettingandofferedtothe
generalpopulation,wastomeasuretheefficacyofKANOPEE,asmartphoneapplication
proposing repeated interactions with a virtual agent to reduce sleep complaints over
17dayscomparedtoanotherapplicationgivingaccesstoanelectronicsleepdiaryonly.
Basedontheliteratureandpreviousstudies,wehypothesizedthatbothappscouldreduce
insomniacomplaintsandimprovesleep,butthatKANOPEEwouldhaveagreaterimpact
oninsomniaandsleepqualitymeasures.
2. MaterialsandMethods
2.1. Design
Thestudydesignwasatwo-groupnon-randomizedcontrolledtrialwithself-selection
sampling. ThefirstgroupofsubjectsdownloadedandusedKANOPEE,whichprovided
interactionswithavirtualcompaniontoobtainpersonalizedrecommendationsforimprov-
J.Clin.Med.2022,11,4387 3of11
ingsleepover17days. AsecondgroupofsubjectsdownloadedMySleepDiarytoobtain
accesstoanelectronicsleepdiaryandarepeatedfollow-uponinsomniacomplaints,which
wasconsideredasthecontrolcondition(nointervention).
Bothappsweredevelopedbyourresearchlab,aredownloadableforfreeonGoogle
PlayStoreandAppleStoreandareavailableonlyinFrance. Aspecificauthorizationfrom
GoogleandApplewasobtainedtoputournon-profitappsonlineduringtheCOVID-19
crisis. ThestudywasapprovedbytheethicalcommitteeofUniversityofBordeauxand
wasregisteredattheUSNationalInstituteofHealth(ClinicalTrials.gov)#NCT05074901.
Methods, results and discussion are described using the CONSORT 2010
reportingguidelines.
2.2. Participants
Targetedcommunicationpromotingtheusageofbothappstohelpwithmonitoring
andregulatingsleepwasmadeonsocialmedia(Instagram,TikTok,Facebook,Twitter),
nationalandregionalnewspapersandTV,anduniversityandhospitalmailinglists, in
ordertoincreasethedownloadrateandreachthemostdiversepopulations. Thereleaseof
bothappswasinlinewithgovernmentcommunicationabouttheprevalenceofsleepand
mentalcomplaintsandassupporttoincreaseawarenessoftheimportanceofsleepduring
theCOVID-19crisis.
FromDecember2020toOctober2021,subjectswereincludedbasedonthefollowing
criteria: (1)havingdownloadedKANOPEEorMySleepDiary;(2)havingcompletedthe
firstinsomniaquestionnairebetweenDecember2020andOctober2021;and(3)beingof
legalage(aged18orolder).
Criteriafornotparticipatingwere: (1)notowningasmartphone;(2)notbeinglocated
in France; (3) having completed the first insomnia questionnaire outside the inclusion
period;or(4)beingyoungerthanage18.
RecruitmentwasperformedonGooglePlayStoreandAppleStorebydownloading
oneofthetwoapps.
Baselinecharacteristicsofuserswerecollectedattheregistrationstepafteracceptance
of informed consent obtained directly on the apps, in accordance with General Data
Protection Regulation (GDPR) and the Commission Nationale de l’informatique et des
libertés(CNIL)requirements.
Bothappscollectedtheusers’informationaboutage(inyears),gender(male/female),
educationallevel(middleschool/highschool/lessthan5yearsofuniversity/morethan
5yearsofuniversity),initialinsomniacomplaints(InsomniaSeverityIndex(ISI),seelater
outcomemeasure)anddepressiveandanxietysymptoms(PatientHealthQuestionnaire-4
(PHQ-4))[20].
All data were collected anonymously and stored on secure servers at University
ofBordeaux.
2.3. Interventions
Usersintheinterventioncondition(KANOPEE)wereinvitedtointeractwithLouise,
avirtualcompanionprovidingscreening,follow-upandpersonalizedrecommendationsto
decreaseinsomniacomplaints.
2.3.1. ScreeningInterview
Screening consisted of administration of the Insomnia Severity Index (ISI) [21,22]
(Figure1A),thenvisualfeedback(green/orange/redvisualscale)(Figure1B),andtheoffer
ofcompletingasleepdiaryforoneweekandthenhavinganotherinterviewatthattime.
Afterthisscreeninginterview,thesleepdiarytabappearedonthebottomofthescreenand
userscouldfilliteverydayandobtainvisualfeedbackontheirsleep(Figure1C).
J. Clin. Med. 2022, 11, x FOR PEER REVIEW 4 of 12
2.3.1. Screening Interview
Screening consisted of administration of the Insomnia Severity Index (ISI) [21,22]
(Figure 1A), then visual feedback (green/orange/red visual scale) (Figure 1B), and the
offer of completing a sleep diary for one week and then having another interview at that
time. After this screening interview, the sleep diary tab appeared on the bottom of the
J.Clin.Med.2022,11,4387 4of11
screen and users could fill it every day and obtain visual feedback on their sleep (Figure
1C).
Figure1. ExampleFsigoufrien t1e. rEfaxacmespolefsK oAf iNntOerPfaEcEes (oAf –KDA)NaOnPdEME (yAS–lDee) panDd iMaryy S(lEe,eFp) Dapiaprys .(E(A,F)) Sapcrpese. n(A-) Screen-
shot of Louise questioning Insomnia Severity Index. (B) Screenshot of visual feedback given after
shotofLouisequestioningInsomniaSeverityIndex. (B)Screenshotofvisualfeedbackgivenafter
screening interview with Louise. (C) Sleep diary and visual feedback on sleep patterns in KA-
screeninginterviewNwOiPthEEL. o(Dui)s eS.cr(eCe)nsShleoet pofd piaerrysoannadlizveids uslaelefpe eredcboamckmoenndsalteioepn gpiavtetner bnys LinouKisAeN dOurPinEgE f.ollow-up
(D)Screenshotofpinertesrovnieawliz. e(Ed) sIlneseopmrneicao Smevmeerintyd aIntidoenx gaidvmeninbisyteLreodu iinse Mdyu rSilnegepf oDllioarwy-. u(Fp) iVntiseurvali efwee.dback on
(E)InsomniaSeveristlyeeIpn pdaetxteardnsm inin Mistye Sreledepin DMiaryyS. leepDiary.(F)Visualfeedbackonsleeppatternsin
MySleepDiary.
2.3.2. Follow-Up Interview
2.3.2. Follow-UpInterOvniee wweek later, KANOPEE users were offered another interview with the virtual
Oneweeklactoemr,pKaAnNionO, PwEhEo upsreorvsidweedr ea osfufmermedarayn ooft hsleereipn tdeiravryie dwatwa,i tahdmthienivsitretruedal tchoem IS-I for the
second time, and then gave personalized recommendations based on ISI answers and on
panion,whoprovidedasummaryofsleepdiarydata,administeredtheISIforthesecond
sleep diary data. The recommendations were simple sentences (e.g., “In the morning,
time,andthengavepersonalizedrecommendationsbasedonISIanswersandonsleep
expose yourself to sunlight or to another source of bright light (luminotherapy, screen) to
diarydata. Therecommendationsweresimplesentences(e.g.,“Inthemorning,expose
improve the functioning of your biological clock”), associated with a picture (Figure 1D).
yourselftosunlightortoanothersourceofbrightlight(luminotherapy,screen)toimprove
thefunctioningofyourbiologicalclock”),associatedwithapicture(Figure1D).Userswere
encouragedtofollowtheserecommendationsonsleephygienerecommendation,stimulus
control,timeinbedrestriction,relaxationandphysicalactivityfor10daysandcontinueto
usethesleepdiary,andtheywereinformedthattheywouldhaveathirdinterview10days
later. Afterthisfollow-upinterview,anewtab“personalizedrecommendations”appeared
atthebottomofthescreensothatuserscouldrefertothematanytime.
2.3.3. FinalInterview
Tendayslater,KANOPEEusershadalastinterviewwithLouise,whoaskedwhich
recommendationsuserswereabletofollow,administeredtheISI,andthen,dependingon
theISIscore,gavetheusertheopportunitytocontinueusingKANOPEEautonomously(if
ISI≤21)orbereferredtoasleepspecialist(ifISI>21).
J.Clin.Med.2022,11,4387 5of11
2.4. ControlCondition
Users of My Sleep Diary had access to the exact same sleep diary proposed in
KANOPEE(Figure1F).Additionally,onceaweek,userscouldcompletetheISIinatextual
interface(Figure1E).ThedifferencescomparedtoKANOPEEweretheabsenceofavirtual
companionadministeringthequestionnaire,theabsenceofpersonalizedrecommendations,
andnoreferraltoaspecialistifcomplaintspersistedaftertwoweeksofuse.
Thepotentialbiasinducedbynon-randomizationwasminimizedasfollows:
Bothapplicationshadthesame“tags”onthedownloadplatforms(i.e.,AppleStore
and Google Play Store), so when a user searched for an app with the words “sleep” or
“diary”or“insomnia”,theyfoundbothappstodownload;
The inclusion period was the same for both apps in order to reduce any seasonal
effectsorthoseattributabletotheCOVID-19pandemic;
Ifusercharacteristicsatbaselinedifferedfromonegrouptoanother,furtheranalyses
wereusedtocontroltheeffectofthosecharacteristics(age,gender,symptomseverity,etc.)
intheoutcomesofinterest.
To increase compliance, a reminder was sent every day from both apps to remind
userstofillintheirsleepdiary,andeveryweektocompletetheISI.Usersdidnotreceive
anyfinancialincentiveforparticipation.
2.5. OutcomeMeasures
TheprimaryoutcomemeasurewastheInsomniaSeverityIndex,aseven-itemself-
reportquestionnairethatprovidesaglobalmeasureofperceivedinsomniaseverity(range
from0to28: 0–7(noclinicalinsomnia),8–14(sub-thresholdinsomnia),15–21(insomnia
ofmoderateseverity),and22–28(severeinsomnia)). TheISIhasbeenvalidatedandhas
provensensitivetochangesininsomniaseveritywithtreatment[22]. Intheintervention
group(KANOPEEusers),theISIwasadministeredbythevirtualcompanion.Inthecontrol
group(MySleepDiaryusers),itwasinatextualformat. Thesecondaryoutcomemeasures
includedchangesinnocturnalsleepindicatorsderivedfromthesleepdiariescompleted
bythesubjects: sleeponsetlatency(SOL),numberofawakenings(NWAK),wakeafter
initialsleeponset(WASO),terminalwakefulness(TWAK),totaltimespentinbed(TIB),
totalsleeptime(TST),andsleepefficiency(SE).Thesesleepindicatorshaveproventheir
validity[23,24]. Thesleepdiarywasthesameinbothapps. Reminderssenteverydayin
theeventofnon-completionreducedtheamountofmissingdata.
2.6. StatisticalAnalyses
2.6.1. SampleSize
Samplesizeandpoweranalysiswerecalculatedbasedonourpreliminaryresults[19]
inwhichISIscoresdifferedbetweenthefirstmeasureandthemeasureafteroneweekof
sleepdiaryintervention(15.60±5.01vs. 13.58±5.21),representinganestimatedEffect
Size=0.4.
For an ANOVA with independent groups (sleep diary versus KANOPEE), a total
samplesizeof684participantsafterthethree-weekfollow-upisneededtoobtainasufficient
statisticalpower(1-βerrprob)=0.80,aneffectsize=0.10(conservativehypothesis)andan
αerrprob=0.05(GPower). Consideringthesamerateofcompletion(10%)andfrequency
ofdownloads(700downloadspermonth)asinourpreviousstudy,theinclusionperiod
hadtolastatleast10monthstoobtaintheminimumtotalsamplesizeof684users.
2.6.2. Descriptive
Quantitativevariableswereexpressedasmean±standarddeviation(SD)andqualita-
tivevariableswereexpressedaspercentage.
2.6.3. ComparativeAnalyses
Univariateanalyseswitht-testcomparisonsforindependentgroupsforcontinuous
variablesorChi2testforcategoricalvariableswereusedtocomparesocio-demographic
J.Clin.Med.2022,11,4387 6of11
andclinicalcharacteristicsofparticipantsbetweenMySleepDiaryandKANOPEEgroups.
Four-wayanalysesofvariance(ANOVAs)withrepeatedfactor“Time”(“screening”: corre-
spondingtoscoresatbaseline,“afterStep1”: correspondingtoscoresafteroneweekof
appuse;and“afterStep2”: correspondingtoscoresafter17daysofappuse),andbetween
subject-factors“Group”(sleepdiaryversusKANOPEE),“Severityofbaselineinsomnia
complaints”(0–7,8–14and15–28)and“Age”(Lessthan50yearsold,Morethan50years
old) were used to analyze ISI and nocturnal sleep characteristics. Age categories were
basedonthemedianageofthestudypopulation.
Chi2testswereperformedtocomparetheproportionofusersineachseveritycategory
ofinsomniacomplaints(none, mild, moderatetosevere)bycondition(sleepdiaryand
KANOPEE)betweenfirstandlasttimepoint(screeningversusafterStep2),andtocompare
the distribution of users’ severity of insomnia complaints between sleep diary versus
KANOPEEateachtimepoint(screening,afterStep1andafterStep2).
Thealphariskthresholdwassetatp=0.05. Statistica®(StatSoftInc. 2010,Statistica
forWindows,Maisons-Alfort,France,Version9.1)wasused.
3. Results
3.1. ParticipantFlow
TheflowchartofparticipantscanbefoundinFigure2. Duringtheinclusionperiod
(i.e.,December2020toOctober2021),8714usersdownloadedthetwoapps(i.e.,KANOPEE
andMySleepDiary),but242userswereexcludedfornotmeetingtheinclusioncriteria
(age<18yearsold). Amongtheremaining8470,5614KANOPEEusersand1834MySleep
J. Clin. Med. 2022, 11, x FOR PEER REDViIaErWy usersdiscontinuedtheinterventionbeforetheend(eitherforgottoanswerord7e leotf e1d2
theapp)andwerethereforeexcluded. Eventually,535KANOPEEusersand489MySleep
Diaryuserswereincludedinthisstudy.
FFiigguurree 22.. PPaarrttiicciippaanntt flflooww..
3.2. Characteristics of Participants
Table 1 shows baseline demographic and clinical characteristics of participants in
the KANOPEE and sleep diary groups. They were predominantly female (two-thirds of
the sample) with moderate to high educational level in both groups. KANOPEE users
were significantly older (p < 0.001), scored slightly higher on insomnia complaints (ISI
score, KANOPEE: 15.2 ± 4.5 vs. My Sleep Diary: 14.2 ± 5.2, p < 0.01) and expressed similar
levels of depression and anxiety on the PHQ-4 questionnaire. There were more people
without professional activity in the KANOPEE group than in the sleep diary group.
Table 1. Socio-demographic and clinical characteristics of participants.
Sleep Diary (n = 489) KANOPEE (n = 535) p-Value
Age, y. (M ± SD) 47.0 ± 13.6 51.2 ± 13.4 <0.001
Female (%) 69.3 64.1 NS
Educational level (%)
Middle school 12.9 10.7
High school 12.7 15 NS
Less than 5 y. of university 56.2 60.7
More than 5 y. of university 18.2 13.6
Professional status (%)
Farmers 3.1 2.8
Artisans 5.3 3.6
<0.001
Senior executive 38.2 36.8
Middle management 13.1 9.7
Employees 18.8 17.2
J.Clin.Med.2022,11,4387 7of11
3.2. CharacteristicsofParticipants
Table1showsbaselinedemographicandclinicalcharacteristicsofparticipantsinthe
KANOPEEandsleepdiarygroups. Theywerepredominantlyfemale(two-thirdsofthe
sample)withmoderatetohigheducationallevelinbothgroups. KANOPEEuserswere
significantlyolder(p<0.001), scoredslightlyhigheroninsomniacomplaints(ISIscore,
KANOPEE:15.2±4.5vs. MySleepDiary: 14.2±5.2,p<0.01)andexpressedsimilarlevels
ofdepressionandanxietyonthePHQ-4questionnaire. Thereweremorepeoplewithout
professionalactivityintheKANOPEEgroupthaninthesleepdiarygroup.
Table1.Socio-demographicandclinicalcharacteristicsofparticipants.
SleepDiary(n=489) KANOPEE(n=535) p-Value
Age,y.(M±SD) 47.0±13.6 51.2±13.4 <0.001
J. Clin. Med. F2e0m22a, l1e1,( %x F)OR PEER REVIEW 69.3 64.1 N8 Sof 12
Educationallevel(%)
Middleschool 12.9 10.7
Highschool 12.7 15 NS
Working class 2.2 0.7
Lessthan5y.ofuniversity 56.2 60.7
Morethan5y.ofuniveRrseittiyred 18.2 11 13.6 19.8
ProfessionalstatuNso(%n)-worker 8.2 5
Farmers Student 3.1 0 2.8 4.3
Artisans 5.3 3.6
ISI initial score (M ± SD) 14.2 ± 5.2 15.2 ± 4.5 <0.01
Seniorexecutive 38.2 36.8
MiddlemanageImSeI ngtroup (%) 13.1 9.7
<0.001
Employees ISI (0–7) 18.8 11.5 17.2 5.8
Workingclass 2.2 0.7 <0.01
ISI (8–14) 37.2 34.6
Retired 11 19.8
Non-workerISI (15–28) 8.2 51.3 5 59.6
SPtuHdQen-t4 initial score (M ± SD) 0 4.3
ISIinitialscore(M±ToStDal) score 14.2±5.2 5.5 ± 2.8 15.2±45.5.1 ± 3.3 NS <0.01
ISIgroup(%) Notes. Y. = Years; M ± SD = Mean ± Standard Deviation; ISI = Insomnia Severity Index; PHQ-4 =
ISI(0–7) Patient Health Qu1e1s.t5ionnaire. 5.8
<0.01
ISI(8–14) 37.2 34.6
ISI(15–28) 3.3. Insomnia Com51p.l3aints 59.6
PHQ-4initialscore(M±SD) The evolution of subjective insomnia complaints between the two groups at base-
Totalscore 5.5±2.8 5.1±3.3 NS
line, after Step 1 and Step 2 is presented in Figure 3.
NoteTsh.eY m.=aiYne aerfsfe;cMt “±GrSoDu=p”M yeiaenld±edS staignndaifridcaDnecvei afotiro nIS;II SsIco=reIn (sFo(m1,n1i0a0S1e)v =e r1i0ty.5I,n pd <e x0;.0P0H1Q) -4=Patient
HealthQuestionnaire.
with significantly lower ISI scores in the KANOPEE group than in the sleep diary group.
A significant interaction between the “Group” factor and the “Time” factor (F(2,2002) =
3.3. InsomniaComplaints
17.3, p < 0.001) created a more marked reduction in ISI score over time in the KANOPEE
Theevolutionofsubjectiveinsomniacomplaintsbetweenthetwogroupsatbaseline,
group than in the sleep diary group (Figure 3).
afterStep1andStep2ispresentedinFigure3.
Figure 3. Insomnia severity index according to sleep diary versus KA NOPEE over time. Note:
FiSgiugrnei fi3.c Iannscoem:n**ia: pse<ve0r.i0ty1 ;in**d*e:xp a<cc0o.r0d0in1g. to sleep diary versus KANOPEE over time. Note: Sig-
nificance: **: p < 0.01; ***: p < 0.001.
Regarding the severity of baseline insomnia complaints, we obtained a significant
interaction with the factor “Time” (F(4,2002) = 24.6, p < 0.001), indicating a greater de-
crease in ISI score over time for the most severe users, whatever the group. The distribu-
tion of KANOPEE and sleep diary users depending on the severity of their insomnia
complaints over time is shown in Figure 4. The proportion of users with severe insomnia
complaints decreased in both groups between the first and last timepoint (sleep diary:
Chi2 = 179.2, ddl = 4, p < 0.001 and KANOPEE: Chi2 = 130.8, ddl = 4, p < 0.001). At
screening, a higher proportion of users with severe insomnia complaints was observed in
the KANOPEE group than in the sleep diary group (Chi2 = 13.3, ddl = 2, p < 0.01). There
was no difference in distribution at the intermediate timepoint between the groups (Chi2
J.Clin.Med.2022,11,4387 8of11
Themaineffect“Group”yieldedsignificanceforISIscore(F(1,1001)=10.5,p<0.001)
withsignificantlylowerISIscoresintheKANOPEEgroupthaninthesleepdiarygroup. A
significantinteractionbetweenthe“Group”factorandthe“Time”factor(F(2,2002)=17.3,
p<0.001)createdamoremarkedreductioninISIscoreovertimeintheKANOPEEgroup
thaninthesleepdiarygroup(Figure3).
Regarding the severity of baseline insomnia complaints, we obtained a significant
interactionwiththefactor“Time”(F(4,2002)=24.6,p<0.001),indicatingagreaterdecrease
inISIscoreovertimeforthemostsevereusers,whateverthegroup. Thedistributionof
KANOPEEandsleepdiaryusersdependingontheseverityoftheirinsomniacomplaints
overtimeisshowninFigure4. Theproportionofuserswithsevereinsomniacomplaints
decreasedinbothgroupsbetweenthefirstandlasttimepoint(sleepdiary: Chi2=179.2,
J. Clin. Med. 2022, 11, x FOR PEER REdVdIElW= 4,p<0.001andKANOPEE:Chi2=130.8,ddl=4,p<0.001). Atscreening,ah9i gohf e1r2
proportionofuserswithsevereinsomniacomplaintswasobservedintheKANOPEEgroup
thaninthesleepdiarygroup(Chi2=13.3,ddl=2,p<0.01). Therewasnodifferencein
d= i0st.1ri,b dudtilo =n 2a,t NthSe).i nOtenr mtheed oiathteerti mhaenpdo,i nthteb etrtwenede nwtahse rgervoeurpsesd(C ahftie2r= S0te.1p, d2 dwli=th2 ,aN gSr)e.aOtenr
tphreopotohretirohna onfd l,etshse stervenerde wpaastireenvtse risne dthaef tKerASNteOpP2EwE igthroaugpr ethataenr pinr otpheo rstlieoenpo dfilaersys sgervoeurpe
p(Cathiei2n t=s 8in.7t, hdedKl A= N2,O pP <E 0E.0g5r)o. uCpotnhsaenquinenthtleys, lae esphidfita troywgarrodusp t(hCeh lio2w=e8r. 7c,ladsdsles= i2n, pte<rm0.s0 5o)f.
Cseovnesreiqtyu eonf tilnys,oamshniifat tcoowmaprldasinthtse sleoewmeerdc ltaos soecsciunr toevrmers toimfsee ivne rtihtey KofAinNsOomPEnEia gcroomuppl.a ints
seemedtooccurovertimeintheKANOPEEgroup.
FFiigguurree 44.. DDisistrtribibuutitoionno fosf leselepepd iadriyarvye rvseurssuKsA KNAONPEOEPuEsEe russdeersp ednedpienngdoinngs eovne rsiteyvoefritthye iorfi nthsoemir ninia-
csoommpnliaai ncotsmopvlearintitms oev.er time.
3.4. NocturnalSleepIndicators
3.4. Nocturnal Sleep Indicators
Table 2 presents nocturnal sleep indicators of sleep diary and KANOPEE users
Table 2 presents nocturnal sleep indicators of sleep diary and KANOPEE users over
overtime.
time.
Regarding sleep onset latency (SOL) and wake after sleep onset (WASO), a de-
Regarding sleep onset latency (SOL) and wake after sleep onset (WASO), a decrease
crease was observed from screening to the last timepoint in both groups (respectively,
was observed from screening to the last timepoint in both groups (respectively, F(2,1980)
F(2,1980)=3.5,p<0.05andF(2,1980)=6.6,p<0.001). Theinteraction“Group”,“Time”,
= 3.5, p < 0.05 and F(2,1980) = 6.6, p < 0.001). The interaction “Group”, “Time”, “Severity of
“Severityofbaselineinsomniacomplaints”yieldedsignificance(respectively,F(4,1980)=5.9,
baseline insomnia complaints” yielded significance (respectively, F(4,1980) = 5.9, p < 0.001
p<0.001andF(4,1980)=8.4,p<0.001)showingthatreducedSOLandWASOovertime
and F(4,1980) = 8.4, p < 0.001) showing that reduced SOL and WASO over time were ob-
wereobservedmostlyinKANOPEEuserswithsevereinitialinsomniacomplaints.
served mostly in KANOPEE users with severe initial insomnia complaints.
Timeinbed(TIB)andterminalwakefulness(TWAK)weredecreasedfromscreening
Time in bed (TIB) and terminal wakefulness (TWAK) were decreased from screen-
to the next two timepoints in both groups (respectively, F(2,1980) = 88.6, p < 0.001 and
ing to the next two timepoints in both groups (respectively, F(2,1980) = 88.6, p < 0.001 and
F(2,1980)=6.5,p<0.001). NodifferencewasobservedinTIBorTWAKreductionbetween
F(2,1980) = 6.5, p < 0.001). No difference was observed in TIB or TWAK reduction between
thetwogroups. TheseverityofinsomniacomplaintsdidnotinfluencethereductioninTIB
the two groups. The severity of insomnia complaints did not influence the reduction in
orTWAK.
TIB or TWAK.
Regarding total sleep time (TST) and sleep efficiency (SE), scores increased in both
groups from screening to the last timepoint (respectively, F(2,1980) = 10.4, p < 0.001 and
F(2,2022) = 4.9, p < 0.001). The interaction “Group”, “Time”, “Severity of baseline insom-
nia complaints” yielded significance (respectively, F(4,1980) = 8.9, p < 0.001 and F(4,2022)
= 9.3, p < 0.001), showing that increased TST and SE over time was observed mostly in
KANOPEE users with severe initial insomnia complaints.
Table 2. Nocturnal sleep characteristics of participants on sleep diary and KANOPEE over time.
Sleep Diary (n = 489) KANOPEE (n = 535)
Screening After Step 1 After Step 2 Screening After Step 1 After Step 2
TIB (hh:mm) 08:25 07:51 07:55 08:37 07:43 07:47
(M ± SD) ± 01:21 ± 01:03 ± 01:02 ± 01:39 ± 01:04 ± 00:58
TST (hh:mm) 06:41 06:48 06:57 05:48 06:15 06:36
(M ± SD) ± 01:40 ± 01:04 ± 00:59 ± 02:23 ± 01:18 ± 01:05
SE (%)
79 ± 17 81 ± 11 83 ± 10 68 ± 26 74 ± 14 74 ± 14
(M ± SD)
J.Clin.Med.2022,11,4387 9of11
Table2.NocturnalsleepcharacteristicsofparticipantsonsleepdiaryandKANOPEEovertime.
SleepDiary(n=489) KANOPEE(n=535)
Screening AfterStep1 AfterStep2 Screening AfterStep1 AfterStep2
TIB(hh:mm) 08:25 07:51 07:55 08:37 07:43 07:47
(M±SD) ±01:21 ±01:03 ±01:02 ±01:39 ±01:04 ±00:58
TST(hh:mm) 06:41 06:48 06:57 05:48 06:15 06:36
(M±SD) ±01:40 ±01:04 ±00:59 ±02:23 ±01:18 ±01:05
SE(%)
79±17 81±11 83±10 68±26 74±14 74±14
(M±SD)
SOL(hh:mm) 00:34 00:30 00:29 00:45 00:37 00:31
(M±SD) ±00:47 ±00:28 ±00:29 ±01:04 ±00:29 ±00:27
WASO(hh:mm) 00:32 00:31 00:28 01:06 00:49 00:39
(M±SD) ±00:43 ±00:33 ±00:28 ±01:38 ±00:41 ±00:34
NWAK(numberofevents)
1.4±1.4 1.3±0.9 1.2±0.9 1.7±1.3 1.5±0.9 1.3±0.8
(M±SD)
TWAK(hh:mm) 00:36 00:34 00:31 00:57 00:50 00:40
(M±SD) ±00:48 ±00:31 ±00:27 ±01:11 ±00:43 ±00:34
Notes. TIB = Time in bed; TST = Total sleep time; SE = Sleep efficiency; SOL = Sleep onset
latency;WASO=Waketimeaftersleeponset;NWAK=Numberofnight-timeawakenings;TWAK=Terminal
wakefulness,Hh:mm=Hoursminutes;M±SD=Mean±StandardDeviation.
Regardingtotalsleeptime(TST)andsleepefficiency(SE),scoresincreasedinboth
groupsfromscreeningtothelasttimepoint(respectively,F(2,1980)=10.4,p<0.001and
F(2,2022)=4.9,p<0.001). Theinteraction“Group”,“Time”,“Severityofbaselineinsomnia
complaints”yieldedsignificance(respectively,F(4,1980)=8.9,p<0.001andF(4,2022)=9.3,
p<0.001),showingthatincreasedTSTandSEovertimewasobservedmostlyinKANOPEE
userswithsevereinitialinsomniacomplaints.
4. Discussion
Thedigitalself-guidedsleephealthinterventionprovidedbyKANOPEEproduced
a significant and clinically meaningful reduction in insomnia symptom severity. This
demonstratesthat,inlinewithpublichealthcampaigns,theregularuseofsmartphone
appsdownloadedwithoutapreviousmedicalconsultationcanimprovesleepcomplaints.
Thisfindingpleadsfortheideaofpromotingautonomousdigitalinterventionspriorto
membersofthegeneralpublicwithsleepcomplaintsconsultingtheirgeneralpractitioneror
specializedmedicalcenters,especiallyduringaperiodoftensionmarkedbytheCOVID-19
crisisandtheincreasingemergenceofsleepcomplaintsinmodernsocieties.
Furthermore, theKANOPEEinterventionhadagreatereffectonsleepcomplaints
thansimplyrecommendingsubjectstomonitortheirsleepschedulesbyusingasleepdiary.
Both applications globally improved ISI scores and reduced TIB, but KANOPEE had a
more significant benefit on sleep efficiency and increased TST. This effect can probably
be explained by the personalized recommendations proposed in KANOPEE, targeting
stimuluscontrolandtimeinbedrestriction,andconsequently,reducingSOLandWASO
overtime. Interestingly,patientswithsevereinsomniaatbaseline(≥15onISI)improved
significantlyovertimeintheKANOPEEgroup,whereasseverepatientsinthesleepdiary
groupdidnotchangeovertime. Thefindingthatanautonomousdigitalinterventioncan
improveinsomniainseverelyaffectedpatients,iftheyfollowtherecommendationsfortwo
weeks,isveryencouragingforimplementationinalargepopulationofpatients.
Several studies have already demonstrated the efficacy of digital CBT-I [9,11–15],
buttheywereconductedasformalclinicaltrialswiththerationaleofparticipatingina
researchstudy.Ontheotherhand,theKANOPEEprojectadoptsanecologicalpublichealth
perspectivebyprovidinghelptothegeneralpopulationinaperiodwhenconsultations
with physicians are difficult to obtain. Its ecological design and its findings constitute
a sound basis for using validated applications like KANOPEE and My Sleep Diary in
membersofthegeneralpopulationexposedtopsychosocialstress.
J.Clin.Med.2022,11,4387 10of11
BycomparingtheeffectsofusingKANOPEEorasleepdiary,weobtainedcomparable
self-monitoringofsleepqualityandregularfeedback,thuscontrollingforaplaceboeffect
and reinforcing the validity of our results. A future development would be to conduct
acontrolledstudywithtext-basedinteractiontohighlighttheadvantagesofinteracting
withvirtualagents. Whilearandomizedcontrolledstudywithtwoarmscouldhavealso
provided interesting insights into the efficacy of both applications, it would suppose a
selectionprocessrequiringhumaninteractions,whichisexactlywhatwewanttoavoidin
thisspecificstudy. Ouraimwastoinvestigatethereal-worldperceptionofbothapps(with
nophysicianintervention)tounderstandhowfuturecampaignscouldbeundertakento
increasethedownloadrate. TheaddedvalueofusingKANOPEEcomparedtoasimple
sleepdiarywouldproveusefulinpublichealthcampaigns.
Animportantlimitationisthatwedidnotconductspecificinterviewstoquestion
KANOPEEusersaboutwhichrecommendationsbestimprovedtheirsleepbecausewe
wantedtoleavetheparticipantsfreetofocusontheiracceptanceoftheapplicationduring
the17daysoftheprogram. Futureresearchshouldinvestigatehowinterventionscouldbe
tailoredtopatients’phenotypesandlevelofacceptance.Researchindedicatedsleepcenters
wouldbemoreappropriatetoexplorethisissue. Ourresultsdemonstrateagoodefficacy
on a 17-day period. It is worth considering further studies to demonstrate the efficacy
ofourappsonlongerperiods. Italsocouldbeinterestingtodemonstratetheefficacyof
KANOPEEapponobjectivemeasurescollectedbyactimetryorpolysomnography.
Thevalidityofinterventionsbasedonautonomousvirtualagentsatthepopulation
level is still a burning issue. However, our results in a sample of over 1000 subjects
underlinethepotentialforusingthesenewautonomousdigitalsolutionsinmedicineand
thebenefitsthattheyrepresentforhealthcaresystems.
AuthorContributions:Conceptualization,P.P.,L.D.andC.M.M.;methodology,P.P.,L.D.,C.M.M.,
J.-A.M.-F. and M.A.; software, E.d.S.; validation, L.D. and E.d.S.; formal analysis, P.S. and L.D.;
investigation, P.P.; writing—original draft preparation, P.P., L.D. and P.S.; writing—review and
editing,C.M.M.,J.-A.M.-F.,J.T.,M.A.andE.d.S.Allauthorshavereadandagreedtothepublished
versionofthemanuscript.
Funding:ThisprojectwassupportedbythegrantsLABEXBRAIN(ANR-10-LABX-43),EQUIPEX
PHENOVIRT (ANR-10-EQPX-12-01) and funding from the Region Nouvelle-Aquitaine (IS-OSA
project,ContractNo:18000389).
InstitutionalReviewBoardStatement:ThestudywasconductedinaccordancewiththeDeclaration
ofHelsinki.AftergettingapprovalbytheUniversityandHospitalscientificcommitteesofBordeaux,
thestudywasregisteredontheUniversityHospitalregisterforGeneralDataProtectionRegulation
(GDPR)approvalbytheFrenchauthorities—Commissionnationaledel’informatiqueetdeslibertés
(CNIL)(CHUBX2020GSP0102).
InformedConsentStatement:Notapplicable.
DataAvailabilityStatement:Notapplicable.
Acknowledgments:WethankYannickLevavasseurandEmericLabbéfordevelopingtheapp.
ConflictsofInterest:C.M.M.hasreceivedresearchgrantsfromIdorsiaandCanopyHealth,served
asaconsultantforEisai,Merck,PearTherapeutics,SunovionandWeightWatchers,andreceived
royaltiesfromtheMapiResearchTrust. Noneofthesearerelatedtothismanuscript. Theother
authorsdeclarenocompetinginterests.
References
1. Baglioni,C.;Altena,E.;Bjorvatn,B.;Blom,K.;Bothelius,K.;Devoto,A.;Espie,C.A.;Frase,L.;Gavriloff,D.;Tuuliki,H.;etal.
TheEuropeanAcademyforCognitiveBehaviouralTherapyforInsomnia:AninitiativeoftheEuropeanInsomniaNetworkto
promoteimplementationanddisseminationoftreatment.J.SleepRes.2020,29,e12967.[CrossRef][PubMed]
2. Ohayon,M.M.Epidemiologyofinsomnia: Whatweknowandwhatwestillneedtolearn. SleepMed. Rev. 2002,6,97–111.
[CrossRef]
J.Clin.Med.2022,11,4387 11of11
3. Pigeon,W.R.;Bishop,T.M.;Krueger,K.M.InsomniaasaPrecipitatingFactorinNewOnsetMentalIllness:ASystematicReview
ofRecentFindings.Curr.PsychiatryRep.2017,19,44.[CrossRef]
4. Pfefferbaum,B.;North,C.S.MentalHealthandtheCovid-19Pandemic.N.Engl.J.Med.2020,383,510–512.[CrossRef]
5. Taquet, M.; Luciano, S.; Geddes, J.R.; Harrison, P.J.BidirectionalassociationsbetweenCOVID-19andpsychiatricdisorder:
Retrospectivecohortstudiesof62354COVID-19casesintheUSA.LancetPsychiatry2021,8,130–140.[CrossRef]
6. Matta,J.;Wiernik,E.;Robineau,O.;Carrat,F.;Touvier,M.;Severi,G.;deLamballerie,X.;Blanché,H.;Deleuze,J.-F.;Gouraud,C.;
etal.AssociationofSelf-reportedCOVID-19InfectionandSARS-CoV-2SerologyTestResultsWithPersistentPhysicalSymptoms
AmongFrenchAdultsDuringtheCOVID-19Pandemic.JAMAIntern.Med.2022,182,19–25.[CrossRef][PubMed]
7. Morin,C.M.;Carrier,J.TheacuteeffectsoftheCOVID-19pandemiconinsomniaandpsychologicalsymptoms.SleepMed.2021,
77,346–347.[CrossRef]
8. Zachariae,R.;Lyby,M.S.;Ritterband,L.M.;O’Toole,M.S.Efficacyofinternet-deliveredcognitive-behavioraltherapyforinsomnia—
Asystematicreviewandmeta-analysisofrandomizedcontrolledtrials.SleepMedRev.2016,30,1–10.[CrossRef]
9. Espie,C.A.;Emsley,R.;Kyle,S.;Gordon,C.;Drake,C.;Siriwardena,A.N.;Cape,J.;Ong,J.C.;Sheaves,B.;Foster,R.;etal.Effectof
DigitalCognitiveBehavioralTherapyforInsomniaonHealth,PsychologicalWell-being,andSleep-RelatedQualityofLife:A
RandomizedClinicalTrial.JAMAPsychiatry2019,76,21–30.[CrossRef][PubMed]
10. Ritterband,L.M.;Thorndike,F.P.;Ingersoll,K.;Lord,H.R.;Gonder-Frederick,L.;Frederick,C.;Quigg,M.S.;Cohn,W.F.;Morin,
C.M.EffectofaWeb-BasedCognitiveBehaviorTherapyforInsomniaInterventionWith1-YearFollow-up: ARandomized
ClinicalTrial.JAMAPsychiatry2017,74,68–75.[CrossRef]
11. Ho,F.Y.Y.;Chung,K.F.;Yeung,W.F.;Ng,T.H.Y.;Cheng,S.K.W.Weeklybriefphonesupportinself-helpcognitivebehavioral
therapyforinsomniadisorder:Relevancetoadherenceandefficacy.Behav.Res.Ther.2014,63,147–156.[CrossRef]
12. Pillai,V.;Anderson,J.R.;Cheng,P.;Bazan,L.;Bostock,S.;Espie,C.A.;Roth,T.;Drake,C.L.TheAnxiolyticEffectsofCognitive
BehaviorTherapyforInsomnia:PreliminaryResultsfromaWeb-deliveredProtocol.J.SleepMed.Disord.2015,2,1017.[PubMed]
13. Ritterband,L.M.; Thorndike,F.P.; Gonder-Frederick,L.A.; Magee,J.C.; Bailey,E.T.; Saylor,D.K.; Morin,C.M.Efficacyofan
Internet-BasedBehavioralInterventionforAdultsWithInsomnia.Arch.Gen.Psychiatry2009,66,692–698.[CrossRef][PubMed]
14. Thiart,H.;Lehr,D.;Ebert,D.D.;Berking,M.;Riper,H.Loginandbreatheout: Internet-basedrecoverytrainingforsleepless
employeeswithwork-relatedstrain—Resultsofarandomizedcontrolledtrial.Scand.J.WorkEnviron.Health2015,41,164–174.
[CrossRef]
15. Vincent,N.;Lewycky,S.LoggingonforBetterSleep:RCToftheEffectivenessofOnlineTreatmentforInsomnia.Sleep2009,32,807–815.
[CrossRef][PubMed]
16. Philip, P.; Dupuy, L.; Morin, C.M.; deSevin, E.; Bioulac, S.; Taillard, J.; Serre, F.Smartphone-BasedVirtualAgentstoHelp
IndividualsWithSleepConcernsDuringCOVID-19Confinement: FeasibilityStudy. J.Med. InternetRes. 2020, 22, e24268.
[CrossRef][PubMed]
17. Philip,P.;Micoulaud-Franchi,J.-A.;Sagaspe,P.;deSevin,E.;Olive,J.;Bioulac,S.;Sauteraud,A.Virtualhumanasanewdiagnostic
tool,aproofofconceptstudyinthefieldofmajordepressivedisorders.Sci.Rep.2017,7,42656.[CrossRef]
18. Dupuy,L.;deSevin,E.;Micoulaud-Franchi,J.A.;Philip,P.Factorsassociatedwithacceptanceofavirtualcompanionproviding
screeningandadvicesforsleepproblemsduringCOVID-19crisis.InProceedingsofthe21stACMInternationalConferenceon
IntelligentVirtualAgents,Faro,Portugal,6–9September2022;AssociationforComputingMachinery:NewYork,NY,USA,2022.
[CrossRef]
19. Dupuy, L.; Morin, C.M.; de Sevin, E.; Taillard, J.; Salles, N.; Bioulac, S.; Auriacombe, M.; Micoulaud-Franchi, J.; Philip, P.
Smartphone-based virtual agents and insomnia management: A proof-of-concept study for new methods of autonomous
screeningandmanagementofinsomniasymptomsinthegeneralpopulation.J.SleepRes.2021,31,e13489.[CrossRef]
20. Kroenke,K.;Spitzer,R.L.;Williams,J.B.W.;Löwe,B.AnUltra-BriefScreeningScaleforAnxietyandDepression:ThePHQ–4.
Psychosomatics2009,50,613–621.[CrossRef]
21. Bastien,C.H.;Vallières,A.;Morin,C.M.ValidationoftheInsomniaSeverityIndexasanoutcomemeasureforinsomniaresearch.
SleepMed.2001,2,297–307.[CrossRef]
22. Morin,C.M.;Belleville,G.;Bélanger,L.;Ivers,H.TheInsomniaSeverityIndex:Psychometricindicatorstodetectinsomniacases
andevaluatetreatmentresponse.Sleep2011,34,601–608.[CrossRef][PubMed]
23. Buysse,D.J.;Ancoli-Israel,S.;Edinger,J.D.;Lichstein,K.L.;Morin,C.M.RecommendationsforaStandardResearchAssessment
ofInsomnia.Sleep2006,29,1155–1173.[CrossRef][PubMed]
24. Morin,C.M.Insomnia:PsychologicalAssessmentandManagement;GuilfordPress:NewYork,NY,USA,1993;Volumexvii,p.238.
